| An overview of meningiomas |
36 |
| HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer |
28 |
| Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study |
25 |
| Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study |
25 |
| Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling |
25 |
| KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer |
24 |
| Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions |
19 |
| Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design |
19 |
| Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? |
18 |
| A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer |
16 |
| The utility of Ga-68-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors |
16 |
| Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing |
15 |
| ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line |
15 |
| OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma |
15 |
| Advances in immunotherapy for acute myeloid leukemia |
15 |
| RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma |
15 |
| The role of IDH mutations in acute myeloid leukemia |
14 |
| PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment |
13 |
| Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care |
13 |
| Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma |
13 |
| IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer |
13 |
| Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma |
12 |
| Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling |
12 |
| Long noncoding RNAs as biotargets in cisplatin-based drug resistance |
12 |
| Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design |
11 |
| Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients |
11 |
| ASTRIS: a global real-world study of osimertinib in > 3000 patients with EGFR T790M positive non-small-cell lung cancer |
11 |
| Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis |
11 |
| JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer |
10 |
| Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC |
10 |
| Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker |
10 |
| A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia |
10 |
| KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer |
10 |
| Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer |
10 |
| Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials |
10 |
| Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer |
10 |
| Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers |
9 |
| Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates |
9 |
| Identification of CDK2 as a novel target in treatment of prostate cancer |
9 |
| Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA |
9 |
| By downregulating PBX miR-526b suppresses the epithelial-mesenchymal transition process in cervical cancer cells |
9 |
| A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer |
9 |
| Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale |
9 |
| Understanding the nuances of microwave ablation for more accurate post-treatment assessment |
9 |
| Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design |
9 |
| Denosumab for the treatment of bone disease in solid tumors and multiple myeloma |
9 |
| Curcumin exerts cytotoxicity dependent on reactive oxygen species accumulation in non-small-cell lung cancer cells |
9 |
| Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib |
9 |
| Necitumumab for the treatment of advanced non-small-cell lung cancer |
8 |
| FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer |
8 |
